Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Patheon Announces First Phase of Additional Investment in Milton Park Facility

Published: Thursday, February 07, 2013
Last Updated: Wednesday, February 06, 2013
Bookmark and Share
UK facility to expand early development capabilities in Europe.

Patheon Inc. has announced plans for additional investment in its Milton Park facility.

Located in Oxfordshire, UK, Milton Park is a dedicated pharmaceutical development services facility focused on early development projects.

As part of its early stage offerings, Milton Park currently provides proof-of-concept and first-in-man development programs for oral dose forms.

It also offers Quick to Clinic™, which provides clinical trial materials as fast as four months from receipt of active pharmaceutical ingredient (API).

This service has been structured to provide support to emerging pharmaceutical companies with promising molecules.

With the first phase of additional investment to Patheon’s Milton Park facility, the company will be able to expand upon the early development capabilities currently being offered, including the introduction of the SoluPath™ program.

SoluPath™ is the first fixed-price, multi-platform solution to improve bioavailability that allows parallel formulation screening using multiple leading edge technologies to review aqueous, lipid-based and solid state formulations.

The result is a unique formulation development program for low solubility/bioavailability molecules, which should facilitate a faster route to the clinic.

The purchase of a new HME screening tool and spray-drier will supplement existing technologies at Milton Park to provide the SoluPath™ service to emerging pharmaceutical companies with poorly soluble molecules.

“The introduction of Solupath™ into Milton Park’s existing capabilities is an exciting addition to Patheon’s service offering in Europe,” said Robin Platt, Senior Director, Operations for Milton Park.

Platt continued, “Poorly soluble compounds are increasingly common in pharmaceutical development and we believe Solupath™ provides a mechanism for identifying the most effective way of improving bioavailability of molecule in these cases.”

Paul Garofolo, Executive Vice President, Global PDS Operations, added, “Solupath™ has been operating successfully in Patheon’s North American facilities. Establishing this capability in Europe is part of Patheon’s global strategy to expand early pharmaceutical development services for our customers.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Patheon Signs Flexible Manufacturing Agreement with Amgen
Company has signed a manufacturing agreement with Amgen to provide flexible manufacturing solutions to meet the growing demand for their innovative human therapeutics.
Thursday, April 28, 2016
Flexible Manufacturing Can Help Pharmaceutical Industry Avoid High Costs
Survey about product launch challenges finds instances of demand forecasts off by more than 50 percent, leading to sales losses and reputation damage.
Thursday, March 17, 2016
Patheon Unveils New Brand and Identity
“A Healthier World. Delivered.™” reflects Company’s focus on helping customers deliver life-changing medications.
Saturday, October 03, 2015
Patheon to Acquire Banner Pharmacaps
Adds balanced product and intellectual property portfolio with complementary technology platforms.
Monday, November 05, 2012
Scientific News
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!